Efficacy and safety of pembrolizumab in combination with olaparib in previously treated recurrent cervical cancer: An open-label, single-arm, phase II study
John P. Diaz(Baptist Hospital of Miami), Manmeet S. Ahluwalia(Baptist Hospital of Miami), E.D. Schroeder(Palmetto General Hospital), Thomas Morrissey(Baptist Cancer Center), Jean-Marie Stephan(Baptist Hospital of Miami), Niloofar Nasseri-Nik(Palmetto General Hospital), Eleftheria Kalogera(Mayo Clinic)
Cited by 0
Related Papers
ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
|Clinical Cancer Research|2020|242
Multiple large bowel resections: Potential risk factor for anastomotic leak
|Gynecologic Oncology|2013|77
Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer
|Oncogene|2021|62
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
|Annals of Surgical Oncology|2017|54